Journal
LIVER INTERNATIONAL
Volume 41, Issue 5, Pages 1044-1057Publisher
WILEY
DOI: 10.1111/liv.14831
Keywords
genetic; inflammatory bowel disease; sclerosing cholangitis
Categories
Funding
- European Crohn's and Colitis Organization (ECCO) [Grant_2017/ECCO/PatrickvanRheenen]
Ask authors/readers for more resources
Whole-exome sequencing was performed on 29 patient-parent trios with early-onset PSC, identifying at least one potentially pathogenic variant in 22 trios. A total of 36 candidate risk genes were prioritized, with variants affecting genes involved in transmembrane transport, immune response, and epithelial barrier function. Further validation and functional evaluation of these genes are required to establish their causal role in early-onset PSC.
BACKGROUND & AIMS Primary sclerosing cholangitis (PSC) is a rare bile duct disease strongly associated with inflammatory bowel disease (IBD). Whole-exome sequencing (WES) has contributed to understanding the molecular basis of very early-onset IBD, but rare protein-altering genetic variants have not been identified for early-onset PSC. We performed WES in patients diagnosed with PSC <= 12 years to investigate the contribution of rare genetic variants to early-onset PSC. METHODS In this multicentre study, WES was performed on 87 DNA samples from 29 patient-parent trios with early-onset PSC. We selected rare (minor allele frequency < 2%) coding and splice-site variants that matched recessive (homozygous and compound heterozygous variants) and dominant (de novo) inheritance in the index patients. Variant pathogenicity was predicted by an in-house developed algorithm (GAVIN), and PSC-relevant variants were selected using gene expression data and gene function. RESULTS In 22 of 29 trios we identified at least 1 possibly pathogenic variant. We prioritized 36 genes, harbouring a total of 54 variants with predicted pathogenic effects. In 18 genes, we identified 36 compound heterozygous variants, whereas in the other 18 genes we identified 18 de novo variants. Twelve of 36 candidate risk genes are known to play a role in transmembrane transport, adaptive and innate immunity, and epithelial barrier function. CONCLUSIONS The 36 candidate genes for early-onset PSC need further verification in other patient cohorts and evaluation of gene function before a causal role can be attributed to its variants.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available